Literature DB >> 17928395

Endothelial dysfunction and C-reactive protein are risk factors for diabetes in essential hypertension.

Francesco Perticone1, Raffele Maio, Angela Sciacqua, Francesco Andreozzi, Giuseppina Iemma, Maria Perticone, Carmine Zoccali, Giorgio Sesti.   

Abstract

OBJECTIVE: Type 2 diabetes and essential hypertension are major risk factors for cardiovascular diseases. Endothelial dysfunction is an early step in the development of atherosclerosis and has been demonstrated in hypertensive and diabetic patients. RESEARCH DESIGN AND METHODS: We designed this study to determine whether forearm endothelial dysfunction is an independent predictor of type 2 diabetes in patients with essential hypertension. We enrolled 400 white never-treated hypertensive outpatients, free of type 2 diabetes at the time of the first evaluation. Endothelium-dependent vasodilation was investigated by intra-arterial infusion of acetylcholine. Insulin resistance was estimated by homeostasis model assessment.
RESULTS: During the follow-up (4.5 +/- 1.6 years), 44 patients developed type 2 diabetes. The event rate was 2.4 events/100 patient-years. In a multivariate Cox regression analysis, the peak percentage increase in acetylcholine-stimulated forearm blood flow (hazard ratio [HR] 0.77 [95% CI 0.61-0.99]; P = 0.04) and C-reactive protein (1.16 [1.03-1.32]; P = 0.01) resulted in the only independent predictors of type 2 diabetes.
CONCLUSIONS: An impaired vasodilatory response to acetylcholine predicts development of type 2 diabetes in patients with essential hypertension. Present data also extend recent findings regarding a possible inflammatory pathogenesis of type 2 diabetes and suggest a new approach in treatment of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928395     DOI: 10.2337/db07-1189

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  30 in total

1.  C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1.

Authors:  Keiji Tanigaki; Chieko Mineo; Ivan S Yuhanna; Ken L Chambliss; Michael J Quon; Ezio Bonvini; Philip W Shaul
Journal:  Circ Res       Date:  2009-05-07       Impact factor: 17.367

2.  Nitric oxide vs insulin secretion, action and clearance.

Authors:  Olga Kruszelnicka
Journal:  Diabetologia       Date:  2013-10-18       Impact factor: 10.122

Review 3.  Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance.

Authors:  Dennis M J Muris; Alfons J H M Houben; Miranda T Schram; Coen D A Stehouwer
Journal:  Rev Endocr Metab Disord       Date:  2013-03       Impact factor: 6.514

4.  Executive functioning and diabetes: The role of anxious arousal and inflammation.

Authors:  Kyle W Murdock; Angie S LeRoy; Tamara E Lacourt; Danny C Duke; Cobi J Heijnen; Christopher P Fagundes
Journal:  Psychoneuroendocrinology       Date:  2016-05-18       Impact factor: 4.905

5.  Hypertension, C Reactive Protein and Metabolic Profile: What is the Scenario in Patients Undergoing Arteriography?

Authors:  Ricardo Jose Tofano; Sandra Maria Barbalho; Marcelo Dib Bechara; Karina Quesada; Claudemir Gregorio Mendes; Marie Oshiiwa
Journal:  J Clin Diagn Res       Date:  2017-08-01

6.  Endothelial progenitor cells predict vascular damage progression in naive hypertensive patients according to sex.

Authors:  Velia Cassano; Giovanni Tripepi; Maria Perticone; Sofia Miceli; Irene Scopacasa; Giuseppe Armentaro; Marta Greco; Raffaele Maio; Marta Letizia Hribal; Giorgio Sesti; Francesco Perticone; Angela Sciacqua
Journal:  Hypertens Res       Date:  2021-09-01       Impact factor: 3.872

Review 7.  Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2010-12-09       Impact factor: 4.162

8.  New-Onset Diabetes, Endothelial Dysfunction, and Cardiovascular Outcomes in Hypertensive Patients: An Illness-Event Model Analysis.

Authors:  Raffaele Maio; Edoardo Suraci; Benedetto Caroleo; Cristina Politi; Simona Gigliotti; Angela Sciacqua; Francesco Andreozzi; Francesco Perticone; Maria Perticone
Journal:  Biomedicines       Date:  2021-06-23

9.  Asymmetric dimethylarginine plasma levels and endothelial function in newly diagnosed type 2 diabetic patients.

Authors:  Angela Sciacqua; Nadia Grillo; Michele Quero; Giorgio Sesti; Francesco Perticone
Journal:  Int J Mol Sci       Date:  2012-10-24       Impact factor: 5.923

10.  Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study.

Authors:  Andrzej Surdacki; Olga Kruszelnicka; Tomasz Rakowski; Aleksandra Jaźwińska-Kozuba; Jacek S Dubiel
Journal:  Cardiovasc Diabetol       Date:  2013       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.